NCT06987669

Brief Summary

This observational study aims to determine the gastric emptying kinetics assessed by ultrasound in healthy volunteers after a standard breakfast and the state of the stomach after a clear liquid diet for 18 /24 hours in patients on GLP-1 agonist. The main questions it seeks to answer are:

  • Is the kinetic after a standard breakfast that includes ( avocado and eggs: high fat) as fast as a standard meal that does not involve this food?
  • Is a clear liquid diet of 18 to 24 hours enough to be an empty-stomach, assessed by Ultrasound in patients on GLP1 agonist? Participants will be asked to do:
  • A baseline Gastric US will be performed for healthy volunteers, and then they will have a standardized breakfast. An hourly or bihourly assessment will be done by the US.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
155

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started May 2025

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
May 2025Dec 2027

First Submitted

Initial submission to the registry

May 8, 2025

Completed
9 days until next milestone

Study Start

First participant enrolled

May 17, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 23, 2025

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

May 23, 2025

Status Verified

April 1, 2025

Enrollment Period

1.6 years

First QC Date

May 8, 2025

Last Update Submit

May 22, 2025

Conditions

Keywords

agonist GLP-1perioperative fasting

Outcome Measures

Primary Outcomes (1)

  • Number of patients with each Grade ( stomach content characteristics) according Perlas et al

    Grade 0 ( empty in supine and RLD), Grade 1 ( empty supine but liquid content on RDL), Grade 3 ( Solid content or fluid with an area of more than or equal to 10 cm2).

    24 hours tops since the starting of the clear fluid diet

Secondary Outcomes (1)

  • Area of the stomach in supine and in RLD assessed by ultrasound

    24 hours tops since the starting of the clear fluid diet

Study Arms (2)

Healthy volunteers after high fat standardized breakfast

GUS will be made

Diagnostic Test: Gastric Ultrasound

Patients on GLP-1 agonist

Patients on GLP-1 agonist after clear fluids diet of 18/24 hrs. GUS will be made.

Diagnostic Test: Gastric Ultrasound

Interventions

Gastric UltrasoundDIAGNOSTIC_TEST

A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)

Also known as: GUS
Healthy volunteers after high fat standardized breakfastPatients on GLP-1 agonist

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy volunteers will be assessed for emptying the stomach after a standardized high-fat meal, by ultrasound. Cohort of patients on a GLP-1 agonist after 18/24 hours of clear fluids.

You may qualify if:

  • years old or older
  • Healthy volunteers or semaglutide users

You may not qualify if:

  • Bariatric surgery
  • Hiatal hernia
  • Impairment to give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 2ObesityOverweight

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Cristian Arzola, MD, MSc

    Universidad de Toronto

    STUDY CHAIR
  • Juan Pablo Ghiringelli

    Universidad de Valparaiso

    STUDY DIRECTOR
  • Miguel vega, MD

    Universidad del Desarrollo

    STUDY DIRECTOR

Central Study Contacts

Javiera Vargas, MD, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

May 8, 2025

First Posted

May 23, 2025

Study Start

May 17, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

May 23, 2025

Record last verified: 2025-04